Escugen Biotechnology Co, Ltd

China-originated, DLL3-targeting antibody-drug conjugates (ADCs) are arousing the interest of global partners at the start of the year, with both Innovent Biologics and Jiangsu Hengrui Medicine announ

Domestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and resea

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R

Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash inject